CD33 and acute myeloid leukemia: To illustrate the platform-characteristic of our anti-CD33-mAB-based nanocarrier, we show that ibrutinib-Cy3.5 can act as an efficient inhibitor of BTK in AML cells, as postulated before [24–26].